This is supported by Zhu et al.’s results [30], he found that miR-27a-3p might be associated with resistance of breast cancer cells to adriamycin treatments, by targeting BTG2 and promoting the PI3K/Akt pathway in breast cancer cells. The gene discussed is BTG2; the disease is breast carcinoma.